Oxaliplatin Injection, Solution
Product Images NDC 0781-9317

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 0781-9317). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxaliplatin Novaplus 01

Chemical structure diagram of oxaliplatin showing a platinum (Pt) center coordinated with a cyclohexane diamine ligand and oxalate groups.*

FDA Label Image

Oxaliplatin Novaplus 02

This is a Kaplan-Meier survival curve chart showing Disease-Free Survival (DFS) probability over time in months for two treatment arms, FOLFOX4 and LV5FU2. The chart includes a legend distinguishing the two arms by line style and provides number of events, hazard ratio with confidence interval, a stratified logrank test p-value, and the number of patients at risk at various time points for each arm.*

FDA Label Image

Oxaliplatin Novaplus 03

A survival curve chart showing disease-free survival (DFS) probability over time in months. The chart compares two treatment arms labeled as FOLFOX4 and LV5FU2, both in DUKES C stage. The solid line represents FOLFOX4 and the dashed line represents LV5FU2. Additional statistics include a hazard ratio and a logrank test p-value.*

FDA Label Image

Oxaliplatin Novaplus 04

A survival curve chart depicting the percentage of patients surviving over 24 months for three treatments: oxaliplatin plus 5-FU/LV, oxaliplatin plus irinotecan, and irinotecan plus 5-FU/LV. Median survival in months is listed for each regimen, with oxaliplatin plus 5-FU/LV showing the highest median survival (19.4 months). The chart includes a p-value indicating statistical significance.*

FDA Label Image

Oxaliplatin Novaplus 05

Packaging label for Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) sterile aqueous solution preservative-free for intravenous use. The single-dose vial is labeled with a caution for cytotoxicity and includes instructions to avoid mixing with sodium chloride solutions. Manufactured by Sandoz Inc, product of Germany. The label features the novaplus logo and storage instructions.*

FDA Label Image

Oxaliplatin Novaplus 06

Oxaliplatin Injection, USP 5 mg/mL sterile aqueous solution in a 100 mg/20 mL single-dose vial carton by Sandoz Inc. The packaging indicates the product is for intravenous use only and is a cytotoxic agent. It includes storage instructions, a barcode, and the novaplus logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.